Tactile Systems Technology, Inc. (TCMD) — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Unaudited results; dollar amounts are in millions unless stated otherwise. The company develops and sells home-use medical devices, primarily for lymphedema treatment (Flexitouch Plus and Entre Plus) and airway clearance (AffloVest). Results are seasonal, with demand typically lower in Q1 as patients begin new insurance years and higher in Q3 and Q4.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Total revenue | $61.1 | $58.8 | +4% |
| Gross profit / margin | $43.4 / 71.1% | $41.5 / 70.5% | Margin +0.6 percentage points |
| Operating loss | $(3.0) | $(3.8) | Loss narrowed $0.8 |
| Net loss | $(2.2) | $(1.9) | Loss widened $0.3 |
| Net loss per diluted share | $(0.09) | $(0.09) | No change |
| Operating cash flow | $0.9 | $(0.5) | Improved $1.4 |
Sales revenue was $53.3 million, up 1%; rental revenue was $7.8 million, up 29%. Lymphedema revenue rose 5% to $52.3 million, while airway-clearance revenue fell 4% to $8.8 million. Gross margin improved, but operating expenses increased 2% to $46.4 million. The lower net result versus the prior-year quarter reflected a smaller income-tax benefit ($0.6 million versus $2.9 million), despite reduced operating loss and a swing from $1.0 million of other expense to $0.2 million of other income. The prior-year quarter also included a $0.7 million earn-out fair-value expense.
Balance sheet, debt and liquidity
- Cash and cash equivalents were $60.7 million at March 31, 2024, versus $61.0 million at December 31, 2023. Current assets were $141.3 million and current liabilities $33.1 million.
- Outstanding credit-agreement borrowings were $28.5 million, all term debt; the reported net note payable was $28.4 million after deferred financing fees. The loan bore interest at 7.16%; quarterly principal installments are $0.75 million, with facility maturity on August 1, 2026.
- The company repaid its revolving-credit balance in December 2023 and reported compliance with its financial covenants at quarter-end. Management believes cash, cash equivalents and operating cash flows will cover working capital, capital expenditure, debt service and other requirements for at least the next 12 months.
- Cash decreased $0.3 million in Q1. Investing cash use was $0.5 million and financing cash use $0.7 million. Q1 2023 financing cash flow included $34.6 million of net proceeds from a public stock offering.
Material changes and management commentary
- Lymphedema growth was attributed to increasing field-sales productivity and strength in the entry-level Entre Plus system. The field team expanded to 269 representatives from 246 a year earlier.
- AffloVest sales were affected by slower placements at one large DME provider after expiration of the COVID-19 Public Health Emergency waiver and a return to pre-emergency eligibility requirements. Medicare revenue fell to $14.2 million from $18.5 million, while private insurers and other payers rose to $31.3 million from $25.4 million; the filing does not attribute those channel movements individually to specific causes.
- Management said inflation and changing prices did not materially affect the quarter and are not expected to have a material effect over at least the next 12 months. It identified possible sensitivities including reimbursement, competition, interest rates, labor and component costs, supplier availability, regulation, acquisitions and product development.
- No full-year revenue or earnings guidance is provided in the filing. Management cautions that Q1 results are not necessarily indicative of full-year results.
Risks, contingencies and other notable items
- A stockholder derivative lawsuit related to allegations also involved in a previously settled securities class action remains pending. The parties reported a non-binding settlement-in-principle in July 2023; a motion to dismiss the amended complaint was pending. The lawsuit seeks unspecified damages.
- Purchase orders outstanding for goods expected within the next year totaled $25.7 million. One vendor represented 23% of purchases in Q1 2024, compared with 29% in Q1 2023.
- The filing identifies an upcoming CEO transition as a risk. The exhibit index references an April 23, 2024 offer letter for Sheri L. Dodd and a transition letter agreement for Daniel L. Reuvers.
- Disclosure controls were judged effective at the reasonable-assurance level, and no material change in internal control over financial reporting was reported for the quarter.
Important facts for investors to verify
- Whether lymphedema growth and Entre Plus momentum continue, and whether AffloVest placements recover following the payer-eligibility change.
- How revenue, margins and cash generation develop through the seasonally stronger second half, and whether operating expenses remain aligned with growth.
- Debt service, covenant headroom, interest-rate exposure and management’s 12-month liquidity assessment.
- Developments in reimbursement and payer policies, dependence on a major vendor and the $25.7 million purchase commitments.
- Status and potential financial impact of the derivative lawsuit and the CEO transition.